Moberg Pharma AB (publ)
STO:MOB

Watchlist Manager
Moberg Pharma AB (publ) Logo
Moberg Pharma AB (publ)
STO:MOB
Watchlist
Price: 18.26 SEK -4.85% Market Closed
Market Cap: 852.6m SEK
Have any thoughts about
Moberg Pharma AB (publ)?
Write Note

Moberg Pharma AB (publ)
Change in Working Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Moberg Pharma AB (publ)
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
Moberg Pharma AB (publ)
STO:MOB
Change in Working Capital
-kr12.2m
CAGR 3-Years
27%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Calliditas Therapeutics AB
STO:CALTX
Change in Working Capital
-kr86.4m
CAGR 3-Years
N/A
CAGR 5-Years
8%
CAGR 10-Years
N/A
Camurus AB
STO:CAMX
Change in Working Capital
-kr87.1m
CAGR 3-Years
-52%
CAGR 5-Years
-45%
CAGR 10-Years
N/A
S
Swedencare AB (publ)
STO:SECARE
Change in Working Capital
-kr194.1m
CAGR 3-Years
-60%
CAGR 5-Years
-94%
CAGR 10-Years
N/A
IRLAB Therapeutics AB
STO:IRLAB A
Change in Working Capital
kr11.6m
CAGR 3-Years
N/A
CAGR 5-Years
46%
CAGR 10-Years
N/A
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Change in Working Capital
kr25.1m
CAGR 3-Years
85%
CAGR 5-Years
16%
CAGR 10-Years
N/A
No Stocks Found

Moberg Pharma AB (publ)
Glance View

Market Cap
836.9m SEK
Industry
Pharmaceuticals

Moberg Pharma AB is a pharmaceutical company, which engages in the development and commercialization of medical products. The company is headquartered in Bromma, Stockholm. The company went IPO on 2011-05-26. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The firm collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. The company is active in more than 35 countries, and operates, among others, through Alterna LLC. The company also owns three Over-The-Counter (OTC) brands in the United States.

MOB Intrinsic Value
0.61 SEK
Overvaluation 97%
Intrinsic Value
Price

See Also

What is Moberg Pharma AB (publ)'s Change in Working Capital?
Change in Working Capital
-12.2m SEK

Based on the financial report for Dec 31, 2023, Moberg Pharma AB (publ)'s Change in Working Capital amounts to -12.2m SEK.

What is Moberg Pharma AB (publ)'s Change in Working Capital growth rate?
Change in Working Capital CAGR 3Y
27%

Over the last year, the Change in Working Capital growth was -785%. The average annual Change in Working Capital growth rates for Moberg Pharma AB (publ) have been 27% over the past three years .

Back to Top